Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs is an innovative treatment for advanced somatostatin‐positive neuroendocrine tumors (NETs). PRRT cannot be performed in Japan because there is no approval or insurance cover so far. METHODS: We relied on...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Noritoshi, Wild, Damian, Kaul, Felix, Shimamura, Takeshi, Takano, Shoko, Takeda, Yuma, Okubo, Naoki, Suzuki, Akihiro, Tokuhisa, Motohiko, Ichikawa, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292713/
https://www.ncbi.nlm.nih.gov/pubmed/34174175
http://dx.doi.org/10.1002/jhbp.1014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292713/
https://www.ncbi.nlm.nih.gov/pubmed/34174175
http://dx.doi.org/10.1002/jhbp.1014

Ejemplares similares